Акинетон

Selected form

Biperiden

Treatment option: Poisoning, Parkinsonism, Extrapyramidal Symptoms

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Акинетон

What is Akineton?

Akineton is a medication containing the active substance biperiden, which belongs to a class of drugs known as anticholinergics. It is primarily utilized to manage movement disorders by influencing certain chemical messengers within the central nervous system.

Mechanism of Action

The medication works by targeting the imbalance between dopamine and acetylcholine in the brain. In conditions where movement control is impaired, there is often an overactivity of acetylcholine. Biperiden acts as an antagonist at cholinergic receptors, helping to reduce this excessive activity and restore a more functional balance. This process helps to diminish muscle rigidity and tremors.

Primary Uses

Akineton is most commonly used in the following contexts:

Parkinson’s Disease: It serves as an adjunctive therapy to address symptoms such as muscle stiffness (rigidity), tremors, and slowness of movement.
Drug-Induced Movement Disorders: It is used to treat extrapyramidal symptoms—such as involuntary muscle contractions, restlessness, or spasms—that can occur as side effects of certain antipsychotic or neuroleptic medications.

Therapeutic Goals

The objective of treatment with Akineton is to improve motor coordination and physical mobility. By relaxing smooth and skeletal muscles affected by neurological imbalances, the medication helps individuals regain better control over their daily physical activities and reduces the discomfort associated with muscle spasms.

Regulatory References

What side effects are possible with Акинетон?

Possible Side Effects and Safety Information

The safety profile of Акинетон (Biperiden) is based on its classification as an anticholinergic agent, with documented adverse reactions primarily affecting the central nervous system, eyes, and gastrointestinal tract, as outlined in official regulatory documents.

Classification of Adverse Reactions

Adverse events are categorized by frequency, which is determined by regulatory bodies based on clinical data. The most frequently observed effects are typically linked to the medicine's core action, while serious events are generally classified as Rare or Very Rare.

System-Organ Class	Common Adverse Reactions
Nervous System	Dizziness, drowsiness
Eye Disorders	Visual impairment, accommodation disorders
Gastrointestinal	Dry mouth, constipation

Serious adverse reactions, though rare, are officially documented and include heightened acute confusion, delirium, and hallucinations, particularly with higher doses or in susceptible patients. The label also lists an increased risk of cerebral seizures or convulsions and the potential for severe urinary retention, especially in individuals with existing prostatic hypertrophy.

Safety Considerations for Specific Populations

Regulatory safety information notes specific concerns for certain groups. Older adults are acknowledged as being more susceptible to central anticholinergic effects, such as confusion and memory impairment. Additionally, caution is noted in patients with impaired liver or renal function due to the potential for altered clearance, which may lead to increased systemic exposure. Biperiden is strictly restricted or contraindicated in patients with untreated narrow-angle glaucoma and obstructive gastrointestinal disorders.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Biperiden (Akineton) presents as the Central Anticholinergic Syndrome, a condition derived from the drug's pharmacological classification. This severe presentation is defined by officially documented clinical manifestations affecting both the central and peripheral systems.

Documented Overdose Manifestations and Outcomes

Domain	Official Regulatory Statement
Central Signs	Delirium, hallucinations, anxiety, disorientation, and seizures are documented. The toxic state can progress to stupor and coma [Source: Regulatory Prescribing Information].
Peripheral Signs	Manifestations include hyperpyrexia (elevated temperature), tachycardia (increased heart rate), mydriasis (dilated pupils), dryness of mucous membranes, and urinary retention [Source: Government Drug Monographs].
Life-Threatening Risk	Overdose carries a risk of severe outcomes, including circulatory collapse, central respiratory paralysis, and cardiac arrest. Untreated overdose may be fatal, particularly in children [Source: Government Clinical Reviews].

Emergency Actions and Required Management

Regulatory documents state that patients must seek emergency medical attention immediately upon suspected overdose. Treatment is focused on symptomatic and supportive therapy. Procedures to limit absorption, such as gastric lavage, are recommended for oral ingestion. Acetylcholinesterase inhibitors (e.g., physostigmine) are listed as an antidote option for severe central effects, though its routine use is noted as controversial. Close monitoring of vital signs and management of hyperpyrexia are required. Reduced antidote doses may be necessary for children or the elderly.

Therapeutic Uses of Акинетон

What Акинетон Treats: Main Uses and Benefits

The medication may be part of symptomatic management for Parkinson's disease and related movement disorders. It is applied to help ease the symptoms of physical rigidity and stiffness and to moderate persistent, involuntary tremors.

This includes conditions characterized by periods of heightened symptoms, such as Parkinsonism (including idiopathic, postencephalitic, and arteriosclerotic forms) and extrapyramidal symptoms caused by other medications. It is often used during phases when symptoms become more noticeable, providing supportive relief when symptoms interfere with routine activities.

“It is relevant when supportive symptom management is appropriate for symptoms of increased neurological or muscular activity.”

The medication is considered relevant in clinical settings marked by the sudden appearance of acute manifestations like dystonia or severe motor restlessness (akathisia). Additionally, it may assist with managing symptoms related to systemic imbalance, such as excessive salivation (sialorrhea) and abnormal sweating, which further contributes to easing the overall symptom load.

Quick Fact	Relief for
Primary Focus	Involuntary Muscle Movement
Acute Use	Sudden Spasms and Dystonia
Chronic Benefit	Stiffness and Tremor

Regulatory References

NIH LiverTox monograph on Biperiden

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Akineton — official regulatory information

Category	Eligibility Status & Constraint
Absolute Contraindications	MUST NOT be used in patients with: Narrow angle glaucoma, Ileus (mechanical obstruction/stenosis in the gastrointestinal tract), Megacolon, Myasthenia gravis, or known Hypersensitivity to biperiden or any excipient.
Restricted/Conditional Use	Use with Caution in: Elderly patients (increased risk of confusional states/delirium); Patients with obstructive diseases of the urogenital tract (e.g., prostatic enlargement); Patients with a history of seizures/epilepsy; and conditions associated with potentially dangerous tachycardia or cardiac arrhythmia.
Age-Group Eligibility	Adults are generally eligible. Children aged 3-15 years are approved for use in drug-induced extrapyramidal symptoms. Elderly patients require cautious dosing due to increased sensitivity.
Physiological Status	Pregnancy is classified as Category C (FDA) and use is only permitted if clearly needed/essential. Use during Lactation is not recommended due to documented presence in milk and unknown effects on the newborn.
Organ Function	Use not established for patients with impaired liver or renal function due to a lack of pharmacokinetic data, necessitating caution.

Official regulatory documents define a clear group of absolute exclusions, such as narrow angle glaucoma and gastrointestinal obstructions, where the drug must be avoided. For all other populations, eligibility is determined by conditional rules that require special caution and risk assessment, particularly for the elderly and those with pre-existing heart or urinary tract conditions. Use during pregnancy and breastfeeding is restricted, categorized as only acceptable when deemed essential due to safety data limitations.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Akineton (Biperiden) can interact with numerous other medications and substances, primarily due to its anticholinergic properties, which can lead to cumulative effects.

Documented Interacting Categories

Other Anti-parkinsonism Medicines: Concomitant use with drugs like levodopa may intensify central and peripheral effects.
Medicines with Anticholinergic Effects: Concurrent use with other anticholinergic agents, such as certain tricyclic antidepressants, antihistamines, or Quinidine, can amplify side effects and may cause the central anticholinergic syndrome.
Psychiatric and CNS-Active Medications: Co-administration with neuroleptics (antipsychotics) or antidepressants can increase the risk of central excitation symptoms, including confusion, delirium, or agitation, particularly in elderly or sensitive patients. Long-term use with antipsychotics may also mask or increase the risk of tardive dyskinesia.
Medicines for Nausea/Vomiting: The effect of drugs like metoclopramide may be reduced by Akineton.

Important Considerations

Dose Adjustment: If an increase in central or peripheral side effects is noted when Akineton is combined with other central nervous system-active drugs, the Akineton dosage may need to be reduced or discontinued.
Alcohol: Consumption of alcohol should be avoided during treatment as it can intensify the drug's central effects and increase the risk of severe intoxication.

Mechanism of Action

Akineton's mechanism is defined by its ability to modulate specific neurochemical pathways in the central nervous system to influence the motor circuit. The drug functions by engaging in competitive antagonism of muscarinic acetylcholine receptors ( mAChRs), particularly the M1 subtype, within the brain. This action directly suppresses the signals generated by acetylcholine, resulting in the attenuation of excitatory signaling in the motor pathways.

The primary site of the mechanism is the corpus striatum, where the drug affects the functional imbalance between the inhibitory dopaminergic system and the overactive excitatory cholinergic system. The dampening of excessive cholinergic drive alters the Dopamine:Acetylcholine ratio, influencing the output of the basal ganglia.

This cascade decreases the magnitude of heightened neural signaling originating from the basal ganglia. This effect is a modulation of the signals that govern skeletal muscle contraction, resulting in the physiological consequence of lowered muscle spindle afferent activity and altered signaling that regulates skeletal muscle contraction.

Dosage and Administration Information

Official Administration Guidelines for Biperiden

The administration of biperiden is governed by specific official guidelines regarding route, dose, and frequency, based on the required speed of action and the nature of the condition being managed. The medicine is available in two approved pharmaceutical forms: 2 mg tablets for oral use and a solution for injection for parenteral administration.

Dosage and Frequency Patterns

The total daily dose of the oral form is determined individually and must be achieved by gradual dose adjustment, starting with the lowest possible amount and slowly increasing to the most favorable dose. The daily dose is divided into multiple single administrations and taken uniformly distributed throughout the day, typically 2 to 4 times daily.

Use Case	Standard Adult Oral Dosing Range	Route of Administration
Maintenance (e.g., Parkinsonism)	3 mg to 16 mg per day	Oral (Tablets)
Acute Events (e.g., drug-induced symptoms)	2.5 mg to 5 mg (single dose)	Intramuscular (IM) or slow Intravenous (IV) Injection

Contextual Administration Instructions

Oral tablets should be taken with sufficient liquid and are best administered during or immediately after a meal in order to reduce the potential for gastrointestinal irritation. When the solution for injection is used, particularly via the intravenous route, it must be administered slowly.

Population-Specific Rules: Dosing in older adults requires caution, and a lower initial dose should be considered, especially in those with certain pre-existing brain conditions. For children aged 3 to 15 years being treated for drug-induced extrapyramidal symptoms, the official oral dose range is generally 1 mg to 6 mg per day in divided doses. The duration of use is often concomitant with the therapy causing the symptoms. Since the 2 mg tablet is cross-scored, it is possible to divide the tablet into equal halves for precise titration.

Recent Clinical Evidence

Research evidence / Overview of studies for Акинетон

Evidence for Use in Parkinsonian Syndromes

Research exploring the use of Акинетон (Biperiden) in Parkinsonian syndromes has been available since its introduction. Studies have primarily examined the role of the medicine as a supporting or adjunctive treatment alongside other therapies. Research examined changes in cardinal motor symptoms, particularly muscular rigidity and tremor, which are outcomes related to physical discomfort. Findings describe patterns observed where specific measures of rigidity and tremor were monitored for change, particularly in groups with postencephalitic or idiopathic Parkinsonism. However, the foundational evidence base is largely comprised of older studies, and long-term effects are not fully established under contemporary research standards.

Evidence for Use in Drug-Induced Extrapyramidal Reactions (EPS)

This evidence base focuses on movement symptoms associated with treatment using other medications. Research examined the use of Biperiden in treating conditions associated with acute or disruptive episodes.

Evidence for Acute Dystonia Management

The evidence available for the management of Acute Dystonia (sudden, sustained involuntary muscle spasms) is derived mostly from clinical observations and case series. This research observed patterns related to the time interval until a symptom change was monitored after administration. Findings describe patterns observed in the studies where a short time interval to symptom change was monitored. Due to the urgent nature of the condition, sample sizes were modest.

Research for Motor Restlessness (Akathisia)

Research for Motor Restlessness (Akathisia) has been evaluated in randomized controlled trials (RCTs) and systematic reviews. Studies monitored patient-reported outcomes describing perceived discomfort using validated scales. Findings were mixed across the available randomized evidence. Research findings suggest that overall certainty for the use in this specific condition remains low, and evidence quality varies across studies.

Key Uncertainties and Evidence Gaps

Clinical research exploring symptom change over time often faces limitations in follow-up duration for short-term symptom patterns. Data for certain groups remain insufficient; for example, specific, dedicated research into the evaluation of Biperiden in older adults has not been extensively reported. Comparative evidence is lacking in certain scenarios. The evidence contributes to understanding what is known—and what is still uncertain—about the research base for this drug.

Key Studies & References

NIH LiverTox: Biperiden

Frequently Asked Questions (FAQ)

Common questions about Акинетон (FAQ)

Q: How long does the effect of one dose of Акинетон usually last?

The official product information includes pharmacokinetic data, which describes how the drug moves through the body. Authoritative sources state that the elimination half-life of the active ingredient, Biperiden, is approximately 24 hours. This data relates to how long the drug remains in the system and is used to inform prescribing decisions.

Q: Is it necessary to avoid alcohol completely while taking Акинетон?

Regulatory documents indicate that alcohol should be used cautiously during treatment. This is because alcohol consumption may intensify the central effects of the drug, which can include increased drowsiness and dizziness.

Q: Can Акинетон be used by older adults?

The medicine is approved for use in older adults, but official prescribing information notes that a lower initial dose is generally advised. This precaution is taken because older patients can be more susceptible to central side effects such as confusion and memory impairment.

Q: Is Акинетон considered safe for use in children?

According to official documents, Biperiden is approved for use in children between the ages of 3 and 15. The approved use is specifically for treating drug-induced movement symptoms, and a defined dosage range is provided for this population.

Q: What is the general process for stopping Акинетон after long-term use?

Regulatory-linked documents note that abrupt discontinuation of the drug is associated with certain risks. Stopping the medicine suddenly can lead to excessive counter-regulation, which may result in a condition sometimes referred to as cholinergic rebound syndrome.

Q: Why is my vision sometimes blurred when using Акинетон?

Visual impairment and accommodation disorders are officially listed as common adverse reactions documented for Biperiden. These effects are related to the drug's primary action in the body.

Q: What does official research say about the effectiveness of Акинетон?

Official research evidence states that studies have examined its role as an adjunctive (supporting) treatment for movement disorders. These studies have monitored changes in specific symptoms, particularly muscular rigidity and tremor, in groups with Parkinsonian syndromes.

Q: What kind of monitoring is typically required while a patient is on Акинетон?

Official warnings advise that special monitoring or dose adjustments may be necessary for patients with certain pre-existing conditions. These conditions include difficulty urinating, epilepsy, heart disease, or impaired liver or kidney function.

Q: What are the official guidelines regarding the use of Акинетон in patients with heart conditions?

Regulatory documents note that caution is required when the medicine is used in patients with heart disease, tachycardia (fast heart rate), or cardiac arrhythmia (irregular heartbeat). This is due to the drug’s potential to cause changes in heart rhythm.

Q: Does taking Акинетон make certain mental health conditions worse?

Official warnings state that patients with depression or any other existing psychiatric illness may require special caution and monitoring. This indicates that these conditions should be managed carefully while the medicine is being used.

Q: Are there generic versions of Акинетон available?

The active component in Акинетон is Biperiden hydrochloride. Authoritative sources confirm that Biperiden hydrochloride is a globally recognized chemical compound with established specifications, suggesting that non-brand or generic formulations are available.

Q: Does the time of day matter when taking Акинетон?

Official guidelines state that the daily dose is typically divided into multiple single administrations taken uniformly distributed throughout the day. Official guidelines note that tablets are often administered during or immediately after a meal, which may help reduce potential gastrointestinal irritation.

Q: Are there any long-term side effects associated with Акинетон use?

Official research summaries note that the foundational evidence base for this medicine is largely comprised of older studies. Consequently, the long-term effects of Biperiden are not fully established under contemporary research standards.

Q: Is dizziness a frequent side effect reported with Акинетон?

Yes, dizziness is listed in official regulatory documents as a Common Adverse Reaction. The classification of 'common' indicates that this side effect is reported frequently in clinical data.

Q: Can Акинетон cause problems with memory or focus?

Official adverse event lists include memory impairment and confusion as documented potential effects. These are central nervous system effects that patients may experience.

Q: Do people typically develop tolerance to Акинетон over time?

Authoritative medical research has examined the possibility of developing tolerance to the drug soon after administration. These studies note that a patient's physiological responses may change over the course of treatment.

Q: What should I do if I experience a severe, rare side effect?

Official safety information notes that serious or severe side effects, such as signs of an allergic reaction or seizures, are considered medical emergencies.

Q: Can taking Акинетон affect driving ability?

Official warnings state that Biperiden may cause drowsiness or blurred vision. Official warnings state that caution is necessary when driving or operating machinery until the effects of the medication are known.

Q: Are there any restrictions on strenuous activity while using Акинетон?

Official warnings note the importance of preventing the body from becoming overheated while using this medicine. The drug may cause decreased sweating, which can impair the body's ability to regulate temperature and increase the risk of heat stroke, particularly with vigorous exercise.

Q: Are there known food or supplement interactions with Акинетон?

Official interaction information focuses on drug-drug interactions and cautions against alcohol use. It also emphasizes the importance of providing a complete list of all medications, including vitamins and herbs (supplements), as interactions may occur.

Q: Is it true that Акинетон can sometimes cause confusion?

Yes, official documents list acute confusion, delirium, and hallucinations as documented Serious Adverse Reactions. These effects are generally linked to higher doses or to patients who are more susceptible to the drug's effects.

Q: Can this medication affect body temperature regulation?

Official warnings state that the drug may cause decreased sweating. This anticholinergic effect can impair the body's ability to regulate temperature, which is why precautions against becoming overheated are advised.

Q: What is the half-life of Акинетон, according to official data?

Pharmacokinetic data from authoritative sources state that the elimination half-life of the active ingredient, Biperiden, is approximately 24 hours. This is a measure of the time it takes for half of the drug to be cleared from the body.

Q: Are there any official reports of withdrawal symptoms when stopping Акинетон?

Regulatory-linked documents advise that abrupt discontinuation should be avoided. This warning is based on the potential for a cholinergic rebound syndrome, which refers to the worsening of underlying symptoms after suddenly stopping the medication.

Q: Does Акинетон interact with blood pressure medications?

Authoritative interaction data notes that the anticholinergic effects of the medicine may potentially exacerbate hypertension (high blood pressure). Therefore, caution is recommended in patients with existing hypertension.

How should Акинетон be stored and disposed of?

How to Store and Dispose of Akineton

Official regulatory documents define specific requirements for the storage, handling, and disposal of Akineton (biperiden) tablets to maintain their stability and safety.

Storage Domain	Official Regulatory Requirement
Temperature	Store at controlled room temperature, typically 25 C (77 F), permitting brief excursions between 15 C and 30 C (59 F and 86 F).
Protection	Keep the medicine in its original, tightly closed, light-resistant container to protect it from moisture and light.
Safety	This medicine must be kept strictly out of the sight and reach of children to prevent accidental poisoning.
Disposal	Do not dispose of unused or expired medicine via household waste or wastewater (e.g., flushing). Follow official national guidelines by consulting a pharmacist or medicine take-back program for proper disposal.